Short for Sisonke Heterologous mRNA-1273 boost after prime with Ad26.COV2.S, the SHERPA Study’s primary objective is to evaluate the effectiveness of the heterologous mRNA-1273 (Moderna) boost against COVID-19 infections and severe COVID-19 disease among health care workers.
The study aims to enroll up to 15 000 Sisonke participants who have received either a single or two doses of Ad26.COV2.S. This will allow the study team to investigate the effectiveness of the Moderna COVID-19 vaccine booster against the new variants in South Africa, as well as provide the South African Health Products Regulatory Authority (SAHPRA) with additional data on this vaccine for potential licensing.
Who can enroll?
You may NOT enrol
How to enroll?
Contact your nearest SHERPA site if you receive the SMS about the SHERPA study or click on the link https://redcap.link/sherpa
Building a healthy nation through research, innovation and transformation
Read more
Generating Knowledge - Impacting Health
Read More
Lessen the impact of the HIV epidemic on individuals, families and communities
Read MoreSAMRC launches a study to evaluate the effectiveness of the Moderna booster, 1 June 2022
• Participants Information and Consent Form - An example of an information sheet and consent form. (Please note that the information and consent process will occur at each clinical research site)
• SHERPA study Frequently Asked Questions
• Participant letter - 7 Oct 2022